Condition
Solid and Hematological Malignancies
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Completed2
Enrolling By Invitation1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05041309Enrolling By InvitationPrimary
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
NCT02636855CompletedPrimary
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
NCT04944771Phase 1CompletedPrimary
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
NCT03391791TerminatedPrimary
Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors
Showing all 4 trials